NTI.AU Neurotech International Ltd
- Market cap
- AUD 22.5M
- P/E
- -
- P/B
- 44.95x
- ROE
- -1,069.9%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is NTI.AU undervalued?
Graham numberThe Graham number of Neurotech International Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neurotech International Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-1,069.9%), below 10%.
ROA 0/1
Return on assets (-238.0%) is below the industry median (-35.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (45.9%) is above the industry median (24.9%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.6 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (45.0x) is above the industry median (4.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Neurotech International Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neurotech International Ltd
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute-onset neuropsychiatric syndrome, and Rett syndrome. It also engages in executin…
Full company profileNeurotech International Ltd financial statements
Neurotech International Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 88.3K | 30.0K | 195K | 77.4K | 206K | 38.3K | 5.96K | 1.96K | 2.44M | - |
| Gross Profit | -170K | -57.0K | -1.16M | -546K | -239K | -535K | 4.22K | -5.87K | 2.44M | - |
| Operating Income | -3.89M | -3.75M | -2.66M | -1.27M | -7.45M | -3.92M | -9.02M | -8.76M | -11.1M | -11.3M |
| EBITDA | -3.63M | -3.44M | -4.80M | -1.21M | 19.3K | -3.36M | -8.98M | -8.24M | -10.7M | -11.3M |
| Net Income | -4.03M | -3.99M | -4.80M | -1.71M | -7.43M | -3.36M | -7.79M | -5.07M | -10.6M | -6.54M |
| EPS | -0.05 | -0.04 | -0.04 | -0.01 | -0.02 | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 4.95M | 4.61M | 653K | 80.8K | 5.01M | 2.02M | 5.31M | 12.2M | 3.24M | 2.75M |
| Total Liabilities | 657K | 376K | 355K | 727K | 1.14M | 593K | 1.35M | 315K | 286K | 2.14M |
| Shareholders' Equity | 4.30M | 4.23M | 297K | -646K | 3.86M | 1.43M | 3.96M | 11.9M | 2.95M | 611K |
| Cash & Short-term Investments | 2.64M | 2.21M | 475K | 12.4K | 4.83M | 1.90M | 5.03M | 11.6M | 3.03M | 2.39M |
| Total Debt | 375K | 29.8K | 126K | 54.2K | - | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.12M | -3.03M | -2.54M | -683K | -2.32M | -2.96M | -6.32M | -4.60M | -9.02M | -4.22M |
| Capital Expenditure | 47.0K | 97.8K | 3.21K | 3.21K | 3.21K | 3.21K | 5.00 | 4.60M | 0.00 | 5.00 |
| Free Cash Flow | -3.17M | -3.12M | -2.54M | -683K | -2.32M | -2.96M | -6.32M | -4.60M | -9.02M | -4.22M |
| Ratios | ||||||||||
| ROE | -93.9% | -94.3% | -1,614.7% | - | -192.4% | -235.1% | -196.7% | -42.6% | -358.7% | -1,069.9% |
| ROA | -81.4% | -86.6% | -735.7% | -2,120.5% | -148.4% | -166.2% | -146.8% | -41.5% | -327.1% | -238.0% |
| Net Profit Margin | -4,565.5% | -13,280.2% | -2,468.3% | -2,214.7% | -3,604.6% | -8,787.4% | -130,759.2% | -258,240.0% | -433.6% | - |
| Debt to Equity | 0.09x | 0.01x | 0.42x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Neurotech International Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | AUD 7.13M | 0.01 | - |
| 2020 | AUD 7.18M | 0.05 | - |
| 2019 | AUD 730K | 0.01 | - |
| 2018 | AUD 3.13M | 0.03 | - |
| 2017 | AUD 4.89M | 0.07 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 8:7 on Feb 1, 2019.
Who owns Neurotech International Ltd
- Insiders 32.81%
- Institutions 4.42%
- Public & others 62.77%
- Shares outstanding 1.32B
- Free float 937M
Neurotech International Ltd company profile
- Company name
- Neurotech International Ltd
- Ticker
- NTI.AU
- ISIN
- AU000000NTI9
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- June
- Address
- 55 Collins Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9498 3132
- Website
- neurotechinternational.com
About Neurotech International Ltd
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute-onset neuropsychiatric syndrome, and Rett syndrome. It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary cannabis strains. The company has a collaboration with The University of Sydney. Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.
Neurotech International Ltd management
5- Mr. Mark DaviesExecutive Chairman
- Associate Prof. Carolyn EllawayChief Medical Officer
- Dr. Bonni Goldstein M.D.Chief Medical Advisor for USA · born 1964
- Mr. Peter James Lawrence Griffiths B.Sc.Chief Executive Officer of AAT Research Ltd · born 1964
- Ms. Alessandra Marie GauvinCompany Secretary